Clinical trial
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
NCT00209222 · European Mantle Cell Lymphoma Network, Other · Unknown status
Key facts
| NCT number | NCT00209222 |
|---|---|
| Title | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL |
| Official title | Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation |
| Lead sponsor | European Mantle Cell Lymphoma Network, Other |
| Collaborators | German Low Grade Lymphoma Study Group Lymphoma Study Association |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Mantle-Cell |
| Intervention type | Drug, Procedure |
| Interventions | Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Cisplatinum, Ara-C, Dexamethasone, BCNU, Melphalan and 9 more |
| Enrollment | 360 |
| Start date | Jul 1, 2004 |
| Primary completion | Dec 1, 2014 |
| Completion | Dec 1, 2014 |
| First posted | Sep 21, 2005 |
| Last update posted | Sep 10, 2012 |
| Countries | France, Germany, Poland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: